- Dec 1, 2023
Myeloma UK Publication, intended for UK Audience: Myeloma – An Introduction - Myeloma Essentials
- Dec 1, 2023
NCCN GUIDELINES FOR PATIENTS: MULTIPLE MYELOMA 2023
- Dec 1, 2023
What is Multiple Myeloma? www.uptodate.com
- Dec 1, 2023
Explore MCT: Join us in creating the most comprehensive platform for Myeloma Clinical Trials
- Dec 16, 2022
Patient Education: Daratumumab & Daratumumab and Hyaluronidase-fihj - Monoclonal Ab - Immunotherapy
- Dec 15, 2022
Patient Education: Lenalidomide - Immunomodulatory Agents - IMIDS
- Dec 10, 2022
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
- Dec 3, 2022
Why is it important to become your own best advocate? HealthTree University Myeloma
- Dec 3, 2022
What is a Myeloma Specialist Why do I Need one and How do I Find One? HealthTree University Myeloma
- Dec 1, 2022
The Binding Site: Freelite Overview
- Dec 1, 2022
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
- Dec 1, 2022
IMF - International Myeloma Foundation: Patient Handbook 2022
- Dec 1, 2022
PE: CDC Guidelines: How to prevent infections (Sepsis) while getting chemotherapy?
- Dec 1, 2022
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
- Dec 1, 2022
National Cancer Institute: Clinical Trials Information for Patients and Caregivers
- Dec 1, 2022
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment
- Dec 1, 2022
How to Prevent Neutropenic Sepsis on Treatment? Know Your ANC (Absolute Neutrophil Count)
- Dec 1, 2022
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
- Dec 21, 2021
Multiple Myeloma Research Foundation - MMRF - Minimal Residual Disease (MRD)